US 12,458,625 B2
Methods and compositions for soft anticholinergic esters
Nicholas S. Bodor, Bal Harbour, FL (US)
Assigned to BODOR LABORATORIES, INC., Miami, FL (US)
Filed by Bodor Laboratories, Inc., Miami, FL (US)
Filed on Mar. 8, 2024, as Appl. No. 18/600,632.
Application 17/848,386 is a division of application No. 15/758,190, granted, now 11,534,422, issued on Dec. 7, 2022, previously published as PCT/US2016/050385, filed on Sep. 6, 2016.
Application 18/600,632 is a continuation of application No. 17/848,386, filed on Jun. 23, 2022, granted, now 11,951,093.
Claims priority of provisional application 62/217,362, filed on Sep. 11, 2015.
Prior Publication US 2024/0261262 A1, Aug. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/40 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/56 (2006.01); A61K 9/70 (2006.01); A61K 47/38 (2006.01); A61K 47/40 (2006.01); A61P 1/02 (2006.01); C07D 207/10 (2006.01); C07D 207/12 (2006.01)
CPC A61K 31/40 (2013.01) [A61K 9/0056 (2013.01); A61K 9/006 (2013.01); A61K 9/2054 (2013.01); A61K 9/7007 (2013.01); A61K 47/38 (2013.01); A61K 47/40 (2013.01); A61P 1/02 (2018.01); C07D 207/10 (2013.01); C07D 207/12 (2013.01)] 13 Claims
 
1. A patch for use in the treatment of sialorrhea, the patch comprising at least one compound having the formula:

OG Complex Work Unit Chemistry
wherein R is methyl or ethyl, said compound having the R stereoisomeric configuration at the 2-position and the R, S or RS stereoisomeric configuration at the 1′ and 3′-positions, or being a mixture thereof, and a pharmaceutically acceptable non-toxic carrier or excipient therefor, wherein the compound of formula (2) is present in an amount of from about 1 mg to about 10 mg per adult dose, or from about 0.02 mg/kg to about 1.0 mg/kg per pediatric dose, wherein the carrier or excipient is suitable for delivery of the at least one compound of formula 2 to the salivary glands.